Portal de investigación
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
ACROTECH BIOPHARMA INC.
Cita
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma. (SPI-BEL-301). ACROTECH BIOPHARMA INC. 2024IP:RAFAEL ANDREU LAPIEDRA.